JPH11510142A - 核酸負荷ポリマー微粒子を使用した遺伝子治療法 - Google Patents

核酸負荷ポリマー微粒子を使用した遺伝子治療法

Info

Publication number
JPH11510142A
JPH11510142A JP9506909A JP50690997A JPH11510142A JP H11510142 A JPH11510142 A JP H11510142A JP 9506909 A JP9506909 A JP 9506909A JP 50690997 A JP50690997 A JP 50690997A JP H11510142 A JPH11510142 A JP H11510142A
Authority
JP
Japan
Prior art keywords
microparticles
bioadhesive
cells
gene
fine particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9506909A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11510142A5 (2
Inventor
マシオウィッツ，イーディス
チョン，ヨン
カリーノ，ジェラルド
ジャコブ，ジュレス・エス
Original Assignee
ブラウン・ユニバーシティ・リサーチ・ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/675,454 external-priority patent/US6248720B1/en
Application filed by ブラウン・ユニバーシティ・リサーチ・ファンデーション filed Critical ブラウン・ユニバーシティ・リサーチ・ファンデーション
Publication of JPH11510142A publication Critical patent/JPH11510142A/ja
Publication of JPH11510142A5 publication Critical patent/JPH11510142A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP9506909A 1995-07-21 1996-07-19 核酸負荷ポリマー微粒子を使用した遺伝子治療法 Ceased JPH11510142A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US136595P 1995-07-21 1995-07-21
US60/001,365 1995-07-21
US08/675,454 US6248720B1 (en) 1996-07-03 1996-07-03 Method for gene therapy using nucleic acid loaded polymeric microparticles
US08/675,454 1996-07-03
PCT/US1996/011990 WO1997003702A1 (en) 1995-07-21 1996-07-19 A method for gene therapy using nucleic acid loaded polymeric microparticles

Publications (2)

Publication Number Publication Date
JPH11510142A true JPH11510142A (ja) 1999-09-07
JPH11510142A5 JPH11510142A5 (2) 2004-08-26

Family

ID=26668935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9506909A Ceased JPH11510142A (ja) 1995-07-21 1996-07-19 核酸負荷ポリマー微粒子を使用した遺伝子治療法

Country Status (6)

Country Link
US (1) US6677313B1 (2)
EP (1) EP0840623B1 (2)
JP (1) JPH11510142A (2)
AU (1) AU714584B2 (2)
CA (1) CA2227287A1 (2)
WO (1) WO1997003702A1 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500744A (ja) * 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
JP2006500015A (ja) * 2002-07-29 2006-01-05 ナノデル テヒノロギーズ ゲーエムベーハー 標的器官へのｄｎａ投与のためのナノ粒子の使用
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
ATE359831T1 (de) * 1997-01-22 2007-05-15 Zycos Inc Mikropartikel zur verabreichung von nukleinsaeuren
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6197229B1 (en) * 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
JP2003519651A (ja) * 2000-01-14 2003-06-24 ブラウン ユニバーシティ リサーチ ファウンデーション 微紛化凍結乾燥粒子
US7029700B2 (en) 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
MXPA02008361A (es) 2000-02-28 2004-05-17 Genesegues Inc Sistema y metodo de encapsulacion de nanocapsulas.
US7256180B2 (en) * 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
JP2003535122A (ja) * 2000-06-02 2003-11-25 ザイコス インク． 生物活性物質のための送達システム
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
EP1347754B1 (en) 2000-11-21 2007-08-29 Michael P. Diamond Compositions for adhesion prevention
WO2003013683A1 (en) * 2001-08-08 2003-02-20 Brown University Research Foundation Methods for micronization of hydrophobic drugs
CA2469718A1 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
NZ535952A (en) 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US7217428B2 (en) * 2004-05-28 2007-05-15 Technology Innovations Llc Drug delivery apparatus utilizing cantilever
WO2007018562A2 (en) * 2004-09-22 2007-02-15 Nanolab, Inc. Nanospearing for molecular transportation into cells
WO2006116065A1 (en) * 2005-04-21 2006-11-02 The Trustees Of Boston College Methods for molecular delivery into cells using nanotube spearing
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
SI2170353T1 (sl) 2007-05-18 2015-09-30 Adiu Tide Pharmaceuticals Gmbh Fosfatno modificirani oligonukleotidni analogi z imunostimulatorno aktivnostjo
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8333754B2 (en) * 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090137866A1 (en) * 2007-11-28 2009-05-28 Searete Llc, A Limited Liability Corporation Of The State Delaware Medical or veterinary digestive tract utilization systems and methods
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
JP7698317B2 (ja) 2019-08-30 2025-06-25 ユニバーシティ オブ ロチェスター がん治療のためのセプチン阻害剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639306A (en) 1968-08-08 1972-02-01 Amicon Corp Encapsulating particles and process for making same
US3615024A (en) 1968-08-26 1971-10-26 Amicon Corp High flow membrane
JPS528795B2 (2) 1971-12-30 1977-03-11
US4637905A (en) 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0248531A3 (en) * 1986-05-02 1988-09-28 Southern Research Institute Encapsulated nucleic acids
ES2053549T3 (es) 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2608942B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US4997904A (en) 1989-08-25 1991-03-05 Nova Pharmaceutical Corporation Aromatic polyanhydride compositions
DE69129696T2 (de) 1990-04-27 1999-02-25 Allergan, Inc., Irvine, Calif. Polymeres arzneimittelabgabesystem
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5516670A (en) 1991-09-30 1996-05-14 Kuehnle; Adelheid R. Magnetophoretic particle delivery method and apparatus for the treatment of cells
US5531925A (en) 1991-10-04 1996-07-02 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
CA2155947C (en) 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
WO1994023699A1 (en) 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles
WO1994023738A1 (en) * 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
WO1995001448A1 (en) 1993-06-30 1995-01-12 Dcv Biologics L.P. A method for introducing a biological substance into a target
EP0804249A2 (en) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5480914A (en) 1994-05-06 1996-01-02 Allergan, Inc. Nonaqueous thixotropic drug delivery suspensions and methods of their use
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
EP0965336A1 (en) * 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500744A (ja) * 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
JP2010047620A (ja) * 1995-11-09 2010-03-04 Health Protection Agency ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
JP2006500015A (ja) * 2002-07-29 2006-01-05 ナノデル テヒノロギーズ ゲーエムベーハー 標的器官へのｄｎａ投与のためのナノ粒子の使用
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質

Also Published As

Publication number Publication date
EP0840623B1 (en) 2007-07-18
US6677313B1 (en) 2004-01-13
CA2227287A1 (en) 1997-02-06
AU714584B2 (en) 2000-01-06
WO1997003702A1 (en) 1997-02-06
EP0840623A4 (en) 2002-05-15
EP0840623A1 (en) 1998-05-13
AU6762396A (en) 1997-02-18

Similar Documents

Publication Publication Date Title
US6677313B1 (en) Method for gene therapy using nucleic acid loaded polymeric microparticles
US6248720B1 (en) Method for gene therapy using nucleic acid loaded polymeric microparticles
JP5484339B2 (ja) 合成物の持続的な放出のためのデンドリマー
US6156348A (en) Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
AU725460B2 (en) Chitosan-gelatin A microparticles
Kumar Nano and microparticles as controlled drug delivery devices
US5985312A (en) Methods and compositions for enhancing the bioadhesive properties of polymers
Stevanovic et al. Poly (lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins
US20040220081A1 (en) Nanoparticulate bioactive agents
JP2001513071A (ja) 転相現象による微粒子の製法
AU6707194A (en) Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
WO2006088473A2 (en) Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
JP2003520810A (ja) 徐放性タンパク質ポリマー
McGee et al. The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility
Truong-Dinh Tran et al. Nanoparticulate drug delivery to colorectal cancer: formulation strategies and surface engineering
DE69637171T2 (de) Zusammensetzungen zur gentherapie die nukleinsäure-beladenen polymer-mikropartikeln enthalten
Puri Novel functionalized polymers for nanoparticle formulations with anti cancer drugs
CN120324640A (zh) 小胶质细胞靶向IL-10 mRNA纳米粒子在缺血性脑卒中免疫治疗中的应用
Iqbal Preparation of submicron particles for theranostic applications: imaging and therapy
Sandor Intracellular delivery of active proteins and genes via erodible nanospheres
Barman et al. 13 Micro-and Nanoparticulate Polymeric Delivery Systems for Nucleic Acid-Based Medicine
Pandey et al. Available Online through Review Article

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061031

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20070323

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070508